cpg
odn
activ
b
cell
impact
gene
ask
gene
express
pattern
bl
cell
affect
trigger
use
cpg
odn
perform
microarray
analysi
compar
odn
versu
untreat
akata
cell
chang
gene
express
upregul
downregul
among
upregul
gene
mainli
interest
involv
cytokin
human
interleukin
chemokin
express
bcell
activ
transcript
apoptosi
fa
gene
preferenti
determin
cell
prolifer
surviv
supplementari
tabl
thirteen
gene
includ
two
regul
cell
cycl
one
transcript
factor
one
involv
bcell
differenti
apoptosi
four
divers
function
four
unknown
function
show
downregul
follow
odn
treatment
supplementari
tabl
earlier
confirm
trigger
akata
cell
odn
increas
express
lead
transloc
valid
marker
bcell
activ
context
measur
express
flow
cytometri
express
increas
upon
odn
treatment
figur
h
express
odn
cell
increas
compar
untreat
cell
figur
b
surprisingli
control
odn
similar
odn
lack
cpg
motif
also
led
increas
express
figur
b
might
reflect
mechan
abil
control
odn
stimul
bl
cell
clarifi
point
use
akata
cell
overexpress
dominantneg
mutant
adaptor
protein
treatment
odn
odn
induc
increas
express
corrobor
first
observ
figur
contrast
neither
odn
odn
significantli
induc
increas
express
akata
cell
figur
final
valid
odn
treatmentinduc
upregul
supplementari
tabl
quantit
realtim
polymeras
chain
reaction
qrtpcr
confirm
activ
western
blot
data
shown
collect
valid
microarray
data
show
trigger
odn
activ
akata
cell
induc
express
moreov
result
indic
odn
use
act
manner
odn
lack
cpg
motif
activ
akata
cell
similar
extent
odn
contain
cpg
motif
trigger
lead
cell
cycl
entri
prolifer
b
chronic
lymphat
leukemia
analyz
cell
cycl
mocktreat
odn
akata
cell
initi
treatment
propidium
iodid
stain
flow
cytometri
cell
phase
time
frame
h
supplementari
figur
treatment
odn
alter
cell
cycl
compar
mock
treatment
similar
result
obtain
cell
data
shown
ebvneg
subclon
akata
thu
although
trigger
odn
result
blcell
activ
base
increas
express
certain
gene
seem
influenc
cell
cycl
treatment
odn
unexpectedli
induc
upregul
akata
cell
manner
similar
treatment
odn
determin
whether
treatment
distinct
ligand
would
similarli
result
effect
cell
surviv
also
explor
whether
class
odn
display
low
specif
b
cell
exert
similar
effect
bl
cell
class
b
odn
possess
high
specif
b
cell
therefor
treat
akata
cell
akata
cell
odn
type
odn
type
b
odn
type
b
control
respect
analyz
viabil
cell
trypan
blue
exclus
assay
peannexin
stain
trypan
blue
exclus
assay
show
treatment
akata
cell
odn
odn
reduc
surviv
cell
within
h
treat
cell
treatment
odn
almost
treat
cell
h
figur
contrast
surviv
akata
cell
reduc
treatment
three
odn
h
figur
find
corrobor
annexin
assay
reveal
viabil
akata
cell
drastic
affect
treatment
class
b
odn
lesser
extent
class
odn
contrast
akata
cell
affect
treatment
odn
h
figur
quantif
figur
thu
treatment
akata
cell
odn
trigger
signal
via
result
cell
death
explor
mechan
odninduc
cell
death
akata
cell
set
investig
whether
caspas
involv
thu
activ
odntreat
akata
cell
detect
use
luminogen
substrat
give
rise
luminesc
signal
proport
activ
trigger
ligand
h
increas
luminesc
signal
twofold
compar
trigger
increas
abolish
treatment
caspas
inhibitor
zvadfmk
figur
indic
trigger
result
increas
caspas
activ
akata
cell
activ
increas
cell
concomitantli
treat
caspas
inhibitor
find
corrobor
use
pi
stain
indic
akata
cell
death
induc
treatment
odn
abrog
caspas
inhibitor
zvadfmk
figur
western
blot
show
parp
cleavag
increas
odn
treatment
reduc
inhibitor
figur
thu
odninduc
cell
death
akata
cell
found
depend
therefor
due
apoptosi
odn
suppress
ebv
lytic
gene
express
akata
cell
primari
b
cell
promot
latent
ebv
may
provid
cell
surviv
observ
akata
cell
death
upon
trigger
ask
whether
absenc
ebv
would
result
even
pronounc
cell
death
follow
trigger
henc
test
whether
agonist
affect
surviv
ebvposit
akata
cell
ebvneg
cell
similar
fashion
treatment
odn
odn
strongli
decreas
percentag
surviv
akata
cell
akata
cell
h
compar
untreat
cell
nevertheless
effect
akata
cell
less
mark
figur
percentag
apoptot
akata
cell
assess
annexin
stain
h
treatment
howev
compar
akata
cell
figur
treatment
odn
odn
odn
result
similar
respect
decreas
viabil
akata
cell
versu
cell
due
apoptosi
treatment
class
odn
exhibit
almost
neg
impact
cell
surviv
compar
treatment
class
b
odn
figur
result
show
ebvneg
cell
exhibit
higher
level
spontan
cell
death
apoptosi
compar
ebvposit
akata
cell
corrobor
lower
effect
trigger
class
odn
compar
trigger
class
b
odn
moreov
result
suggest
presenc
ebv
prevent
ebvposit
akata
cell
triggeringinduc
cell
death
compar
ebvneg
cell
next
investig
whether
observ
ebvposit
versu
ebvneg
bl
cell
hold
true
bl
cell
akata
end
use
ebvposit
bl
cell
mutui
ebvneg
bl
cell
bjab
ramo
treatment
odn
odn
affect
mutui
cell
bjab
cell
surviv
figur
decreas
ramo
cell
surviv
h
figur
thu
surviv
bl
cell
follow
trigger
consider
differ
distinct
bl
cell
seem
depend
presenc
absenc
ebv
import
role
bcell
lymphoma
biolog
seem
act
autocrin
growth
previous
report
corrobor
strong
induct
akata
cell
follow
trigger
odn
supplementari
tabl
nevertheless
treatment
result
drastic
akata
cell
death
figur
suggest
latter
could
prevent
induct
express
otherwis
recent
report
suggest
treatment
odn
chronic
lymphocyt
leukemia
b
cell
mediat
cell
therefor
treat
akata
cell
akata
cell
odn
recombin
combin
thereof
concentr
base
peak
protein
concentr
induc
odn
treatment
akata
addit
odn
treatment
reiter
h
fraction
bl
cell
expect
treatment
odn
h
reduc
viabil
akata
cell
reduc
viabil
akata
cell
compar
treatment
figur
reiter
treatment
odn
h
reduc
viabil
akata
cell
compar
onetim
treatment
reduc
viabil
akata
cell
figur
treatment
h
also
reduc
viabil
akata
cell
akata
cell
compar
treatment
treatment
counteract
odn
treatmentinduc
reduct
bl
cell
viabil
decreas
viabil
akata
cell
affect
treatment
figur
thu
maxim
neg
impact
odn
cell
surviv
akata
cell
occur
one
treatment
moreov
chang
number
viabl
akata
cell
rescu
akata
cell
odn
treatmentinduc
cell
death
suggest
counteract
triggeringinduc
cell
activ
result
death
akata
cell
respons
cell
death
distinct
surviv
bl
cell
follow
trigger
odn
cpg
could
distinct
magnitud
ensu
cellular
respons
induct
follow
odn
cpg
treatment
regard
surrog
marker
magnitud
cell
activ
mediat
trigger
thu
assess
mrna
express
bl
cell
treat
odn
odn
five
bl
cell
line
test
express
mrna
follow
treatment
odn
valu
peak
preferenti
h
post
treatment
figur
peak
mrna
express
level
vari
transcript
hmb
ramo
bl
cell
transcript
mutui
bl
cell
treatment
odn
also
result
induct
mrna
express
lower
level
except
akata
cell
similar
variat
result
observ
analyz
protein
level
figur
thu
trigger
distinct
bl
cell
result
broad
rang
mrna
protein
express
level
magnitud
level
seem
independ
ebv
statu
next
determin
mrna
express
level
bl
cell
qrtpcr
although
distinct
bl
cell
show
sixfold
differ
rel
mrna
express
level
figur
odn
treatmentinduc
mrna
peak
express
level
correl
rel
mrna
express
level
figur
collect
trigger
distinct
bl
cell
result
distinct
mrna
express
link
presenc
absenc
ebv
correl
mrna
express
level
polymorph
patient
link
differ
outcom
inflammatori
diseas
develop
hypothes
polymorph
could
possibl
explan
observ
thu
isol
genom
dna
bl
cell
line
analyz
presenc
polymorph
found
specif
snp
cell
line
allow
segreg
bl
cell
line
three
group
tabl
ga
akata
akata
gg
ramo
gg
mutui
bjab
subgroup
correl
degre
blcell
surviv
respons
odn
treatment
figur
suggest
distinct
blcell
respons
tlr
trigger
may
depend
snp
present
next
analyz
snp
genom
dna
primari
bl
blood
healthi
individu
inde
found
snp
detect
bl
cell
line
primari
bl
sampl
blood
healthi
individu
tabl
importantli
snp
frequenc
statist
significantli
differ
bl
cell
line
primari
bl
blood
healthi
individu
respect
suggest
direct
respons
agonist
depend
snp
could
import
factor
regard
treatment
bl
patient
trigger
analyz
effect
agonist
bl
cell
line
vitro
model
bcell
tumor
found
treatment
ligand
induc
distinct
cytokin
express
cell
death
respons
distinct
bl
cell
cell
death
depend
signal
ii
occur
concomitantli
activ
could
suppress
pan
caspas
inhibitor
iii
depend
presenc
absenc
ebv
tumor
cell
iv
associ
snp
gene
result
suggest
individu
vitro
pretest
bl
respons
cpg
odn
could
help
predict
outcom
therapeut
trigger
tailor
adjuv
molecular
treatment
bl
observ
bl
cell
differ
origin
show
distinct
cell
surviv
follow
trigger
novel
previous
demonstr
trigger
counteract
lytic
ebv
reactiv
bl
cell
promot
latent
ebv
associ
bcell
observ
cpg
type
b
odninduc
cell
death
apoptosi
ebvposit
akata
ebvneg
cell
much
lower
extent
ebvposit
ebvneg
bl
cell
line
test
thu
ebv
statu
tumor
cell
rule
respons
bl
cell
trigger
bl
cell
consist
upregul
express
influenc
develop
growth
b
act
autocrin
growth
factor
differ
bcell
importantli
neither
prevent
enhanc
cell
death
induc
trigger
antiinflammatori
cytokin
inhibit
immun
effect
would
detriment
cancer
therapi
base
intact
enhanc
immun
unintend
prolifer
malign
cell
could
provok
thu
function
cpg
type
b
odninduc
express
bl
cell
seem
consider
differ
chronic
lymphocyt
leukemia
b
cell
report
undergo
surprisingli
odn
induc
cell
death
extent
odn
odn
bind
contrast
lead
signal
cell
chang
secondari
structur
therefor
examin
whether
downstream
signal
via
involv
induct
cell
death
inde
experi
use
akata
cell
overexpress
dominantneg
mutant
indic
odn
induc
cell
death
bl
cell
manner
other
demonstr
odn
induc
cell
death
independ
cpg
motif
even
wholeodn
anoth
pathway
trigger
cpg
odn
describ
monocyt
involv
activ
src
famili
kinas
lyn
experi
bl
cell
death
induc
trigger
correl
increas
caspas
activ
caspasedepend
thu
like
due
apoptosi
bl
cell
line
test
differ
mrna
express
level
snp
mrna
express
correl
cell
death
respons
trigger
distinct
snp
role
snp
bl
unknown
start
investig
analyz
frequenc
given
snp
bl
patient
healthi
individu
found
similar
recent
report
suggest
polymorph
also
detect
confer
increas
risk
nonhodgkin
lymphoma
peopl
portug
itali
unit
associ
c
allel
lack
cell
death
upon
trigger
observ
mutui
bjab
bl
cell
line
strike
allow
establish
causal
link
justifi
hypothesi
distinct
cell
death
respons
upon
cpg
odn
treatment
bl
cell
may
link
snp
notabl
c
allel
exhibit
greater
affin
addit
transcript
bind
site
may
lead
increas
product
proinflammatori
henc
presenc
c
allel
seem
result
enhanc
activ
follow
trigger
may
lead
protect
odn
cpg
treatmentinduc
apoptosi
observ
bl
cell
without
c
allel
conclus
therapeut
trigger
appear
doubleedg
sword
may
induc
apoptosi
enhanc
lymphoprolifer
find
suggest
effect
agonist
bl
cell
test
vitro
instal
therapi
snp
bl
patient
evalu
potenti
biolog
marker
respons
treatment
target
innat
immun
ebvposit
bl
cell
line
akata
mutui
ebvneg
bl
cell
line
akata
bjab
ramo
grown
rpmi
supplement
heatinactiv
fetal
calf
serum
streptomycin
mgml
penicillin
uml
lglutamin
mm
ebvposit
bl
akata
cell
express
dominantneg
akata
grown
medium
supplement
mgml
promega
mannheim
germani
bl
retriev
databas
institut
surgic
patholog
univers
hospit
zurich
pathopro
softwar
institut
medic
softwar
germani
bl
diagnosi
perform
accord
classif
tumor
hematopoiet
lymphoid
dna
extract
paraffinembed
wholetissu
section
accord
standard
procedur
studi
accord
swiss
law
approv
offici
author
ethic
committe
canton
zurich
peripher
blood
collect
healthi
blood
donor
age
year
randomli
select
accord
criteria
swiss
red
wholegenom
dna
extract
dneasi
blood
tissu
kit
qiagen
hombrechtikon
switzerland
accord
manufactur
instruct
genotyp
polymorph
tc
ga
done
tetraprim
assay
previous
cell
split
densiti
cellsml
ligand
odn
type
odn
type
b
odn
type
b
control
appli
concentr
odn
labforceinvivogen
nunningen
switzerland
sequenc
odn
base
phosphodiest
capit
letter
phosphorothio
lower
case
odn
full
phosphorothio
backbon
odn
full
phosphorothio
backbon
akata
cell
mock
treat
treat
harvest
h
later
total
rna
isol
rneasi
mini
kit
qiagen
accord
manufactur
instruct
microarray
analysi
perform
function
genom
center
zurich
univers
zurich
zurich
switzerland
human
exon
st
array
chip
affymetrix
santa
clara
ca
usa
genespr
gx
softwar
agil
technolog
basel
switzerland
use
analysi
least
twofold
chang
gene
express
upregul
downregul
treat
versu
mocktreat
sampl
regard
signific
total
rna
extract
cell
rneasi
kit
qiagen
dna
remov
dnafre
ambion
europ
huntingdon
cambridgeshir
uk
purifi
rna
use
gener
cdna
highcapac
cdna
revers
transcript
kit
appli
biosystem
rotkreuz
switzerland
quantit
realtim
pcr
perform
specif
taqman
primer
probe
abi
appli
biosystem
data
analyz
softwar
appli
biosystem
delta
cycl
threshold
ct
valu
respect
gene
normal
hmb
cell
stain
fitc
mous
antihuman
igm
clone
mous
antihuman
igg
clone
pe
mous
antihuman
igd
clone
respect
isotyp
control
fitc
isotyp
control
clone
mous
isotyp
control
clone
pe
mous
isotyp
control
clone
antihuman
cat
bd
bioscienc
allschwil
switzerland
min
dark
cell
count
flow
cytomet
facscanto
ii
bd
bioscienc
assess
apoptot
necrot
dead
viabl
cell
cell
harvest
wash
phosphatebuff
salin
pb
resuspend
annexin
v
bind
buffer
mm
nacl
mm
mm
hepe
ph
incub
annexin
v
bd
bioscienc
min
room
temperatur
dark
addit
annexin
v
bind
buffer
cell
analyz
facscanto
ii
flow
cytomet
bd
bioscienc
discern
dead
viabl
cell
treat
cell
stain
pi
sigmaaldrich
chemi
gmbh
buch
switzerland
min
room
temperatur
analyz
facscanto
ii
flow
cytomet
bd
bioscienc
total
protein
lysat
obtain
lyse
cell
ripa
complet
buffer
mm
trishcl
ph
mm
nacl
mm
edta
complement
sd
edtafre
proteas
inhibitor
cocktail
roch
rotkreuz
switzerland
cell
extract
pass
time
syring
protein
content
determin
use
pierc
bca
protein
assay
kit
thermoscientif
erembodegem
belgium
accord
manufactur
instruct
analyz
protein
express
western
blot
protein
load
nupag
bistri
gel
life
technolog
zug
switzerland
subject
sdspage
electrophoresi
transfer
electrophoret
nitrocellulos
membran
ge
healthcar
glattbrugg
switzerland
incub
rabbit
antiparp
antibodi
rabbit
antibodi
subsequ
antirabbit
igg
hrplink
antibodi
dilut
cell
signal
technolog
allschwil
switzerland
signal
detect
ecl
western
blot
detect
reagent
ge
healthcar
imag
use
fujifilm
dielsdorf
switzerland
imag
reader
fujifilm
protein
concentr
determin
supernat
cultur
standard
captur
elisa
readysetgo
ebiosci
vienna
austria
accord
manufactur
instruct
plate
read
nm
substrat
develop
cytokin
concentr
determin
extrapol
standard
curv
activ
assess
caspaseglo
assay
accord
manufactur
protocol
promega
wallisellen
switzerland
cell
dispens
cellsmlwel
plate
treat
ligand
incub
h
end
incub
period
caspaseglo
reagent
ad
cell
suspens
whitewal
plate
incub
room
temperatur
h
luminesc
intens
determin
use
synergi
ht
multidetect
micropl
reader
biotek
luzern
switzerland
one
day
experi
cell
split
densiti
cellsml
next
day
cell
incub
pg
immunotool
friesoyth
germani
indic
time
point
concentr
correspond
protein
concentr
induc
odn
akata
